AbbVie/$ABBV
14:30
15:25
16:15
17:10
18:00
1D1W1MYTD1Y5YMAX
About AbbVie
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
Ticker
$ABBV
Sector
Primary listing
NYSE
Employees
55,000
Headquarters
Website
AbbVie Metrics
BasicAdvanced
$406B
174.08
$1.32
0.35
$6.56
2.85%
Price and volume
Market cap
$406B
Beta
0.35
52-week high
$244.81
52-week low
$164.39
Average daily volume
6M
Dividend rate
$6.56
Financial strength
Current ratio
0.725
Quick ratio
0.468
Long term debt to equity
-2,426.972
Total debt to equity
-2,649.057
Dividend payout ratio (TTM)
481.49%
Interest coverage (TTM)
7.38%
Profitability
EBITDA (TTM)
29,519
Gross margin (TTM)
71.46%
Net profit margin (TTM)
4.00%
Operating margin (TTM)
35.65%
Effective tax rate (TTM)
-44.28%
Revenue per employee (TTM)
$1,080,000
Management effectiveness
Return on assets (TTM)
9.59%
Return on equity (TTM)
137.96%
Valuation
Price to earnings (TTM)
174.08
Price to revenue (TTM)
6.818
Price to book
-2,219.1
Price to tangible book (TTM)
-4.39
Price to free cash flow (TTM)
20.66
Free cash flow yield (TTM)
4.84%
Free cash flow per share (TTM)
11.127
Dividend yield (TTM)
2.85%
Forward dividend yield
2.85%
Growth
Revenue change (TTM)
7.40%
Earnings per share change (TTM)
-53.98%
3-year revenue growth (CAGR)
1.04%
10-year revenue growth (CAGR)
10.53%
3-year earnings per share growth (CAGR)
-43.95%
10-year earnings per share growth (CAGR)
-2.63%
3-year dividend per share growth (CAGR)
5.17%
10-year dividend per share growth (CAGR)
12.50%
What the Analysts think about AbbVie
Analyst ratings (Buy, Hold, Sell) for AbbVie stock.
AbbVie Financial Performance
Revenues and expenses
AbbVie Earnings Performance
Company profitability
AbbVie News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
FAQs
What’s the current market cap for AbbVie stock?
AbbVie (ABBV) has a market cap of $406B as of December 26, 2025.
What is the P/E ratio for AbbVie stock?
The price to earnings (P/E) ratio for AbbVie (ABBV) stock is 174.08 as of December 26, 2025.
Does AbbVie stock pay dividends?
Yes, the AbbVie (ABBV) stock pays dividends to shareholders. As of December 26, 2025, the dividend rate is $6.56 and the yield is 2.85%. AbbVie has a payout ratio of 481.49% on a trailing twelve-month basis.
When is the next AbbVie dividend payment date?
The next AbbVie (ABBV) dividend payment is scheduled for February 17, 2026.
What is the beta indicator for AbbVie?
AbbVie (ABBV) has a beta rating of 0.35. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.